EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Zanubrutinib, a New Bullet Against Chronic Lymphocytic Leukemia Even When Localized in Central Nervous System

Maria D'Amato iD, Claudia Baratè, Giulia Cervetti, Mariacostanza Caparello, Valerio Ortenzi, Antonio Giuseppe Naccarato, Edoardo Benedetti, Sara Galimberti iD

Case Reports in Hematology · 2026-01 · 2026 (1)

DOI: 10.1155/crh/4126471 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Case Reports in Hematology, online erschienen am 17.08.2026. Verfasst von Maria D'Amato und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Via Roma, 67, Pisa, Italy, unipi.it. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università di Pisa.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Central nervous system (CNS) and extralymphatic involvement in chronic lymphocytic leukemia (CLL) is rare and associated with poor prognosis. Case Description We report the case of a 45‐year‐old woman with refractory CLL who developed CNS and extralymphatic lesions after three prior lines of therapy, including rituximab–bendamustine, rituximab–idelalisib, and rituximab–venetoclax. Third‐line treatment with rituximab–venetoclax led to partial remission (PR), followed by a 2‐month treatment‐free interval before the emergence of a new lesion. Treatment with zanubrutinib, a second‐generation Bruton’s tyrosine kinase inhibitor (BTKi), was initiated, resulting in significant clinical improvement and near‐complete resolution of lesions.

Discussion

Zanubrutinib’s enhanced blood–brain barrier (BBB) penetration and favorable safety profile make it a promising option for CNS–CLL and also for other extralymphatic lesions.

Conclusion

This case underscores the potential of zanubrutinib in addressing challenging CLL presentations.

Schlagwörter

Stichwörter der Autor:innen

CLLcase reportibrutinibvenetoclaxzanubrutinib

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Via Roma, 67, Pisa, Italy, unipi.it.
  • ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan, Italy, ospedaleniguarda.it.
  • Department of Laboratory Medicine and Pathology, Pathology Unit, Cisanello Hospital AOUP, Via Paradisa, 2, Pisa, Italy.

ORCID-Profile: Maria D'Amato, Sara Galimberti

Förderung

  • Università di Pisa

Zitieren

APA

D'Amato, M., Baratè, C., Cervetti, G., Caparello, M., Ortenzi, V., Naccarato, A. G., Benedetti, E., & Galimberti, S. (2026). Zanubrutinib, a New Bullet Against Chronic Lymphocytic Leukemia Even When Localized in Central Nervous System. Case Reports in Hematology, 2026(1). https://doi.org/10.1155/crh/4126471

Vancouver

D'Amato M, Baratè C, Cervetti G, Caparello M, Ortenzi V, Naccarato AG, et al. Zanubrutinib, a New Bullet Against Chronic Lymphocytic Leukemia Even When Localized in Central Nervous System. Case Reports in Hematology. 2026;2026(1). doi:10.1155/crh/4126471

BibTeX
@article{DAmato2026,
  author = {D'Amato, Maria and Baratè, Claudia and Cervetti, Giulia and Caparello, Mariacostanza and Ortenzi, Valerio and Naccarato, Antonio Giuseppe and Benedetti, Edoardo and Galimberti, Sara},
  title = {Zanubrutinib, a New Bullet Against Chronic Lymphocytic Leukemia Even When Localized in Central Nervous System},
  journal = {Case Reports in Hematology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crh/4126471}
}
Kostenlos starten →